Happiness Biotech Starts Offering Kingdomway Coenzyme Q10 in Its Experience Stores
NANPING, China, Nov. 16, 2020 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, announced today that the Company's experience stores started offering Coenzyme Q10 - a best-selling product from Xiamen Kingdomway Group Company ("KDW", SZSE: 002626).
Coenzyme Q10 is a vitamin-like substance that is produced naturally by the human body. Research suggests coenzyme Q10 may help treat or prevent disease ranging from diabetes,migraines to Alzheimer's disease, as well as slow signs of aging. KDW, founded in 1997, is the world's largest manufacturer of coenzyme Q10. KDW is currently publicly listed on the Shenzhen Stock Exchange.
"Coenzyme Q10 Capsule is one of the most popular nutrition supplement products in China. At present, we have 26 experience stores all over China and formed a certain scale effect. Adding Coenzyme Q10 Capsule in our product offerings brings greater market influence and sales volume to our experience stores. This is just a beginning of our plan to further diversify our product series and improve the sales performance of the stores," said Mr. Xuezhu Wang, CEO of the Company.
About Happiness Biotech Group Limited
Headquartered in Nanping, China, Happiness Biotech Group Limited is an innovative China-based nutraceutical and dietary supplements producer focused on the research, development, manufacturing and marketing of a variety of products made from Chinese herbal extracts and other ingredients. The Company's goal is to provide high-quality products to our consumers. Over the past 14 years, the Company has established a product portfolio consisting of 32 PRC National Medical Products Administration registered "Blue-Cap" SKUs of nutraceutical and dietary supplements products. For more information, please visit: www.happ.org.cn.
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China, the COVID-19 outbreak and its impact on our operations and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
SOURCE Happiness Biotech Group Limited